news
our blog
Poster Prize award at the GRK2243 Symposium Understanding Ubiquitylation: From Molecular Mechanisms to Disease, 2025
We congratulate Dr Cara Ellison from the University of Oxford with the Poster Prize award at the GRK2243 Symposium in Würzburg.
Live cell delivery of ubiquitin reagents by bead loading.
We launched a new protocol for intracellular delivery of our reagents: In protocol P010, (also in our resource download center), we highlight a straightforward, mild and cost-effective...
First Poster Prize award at the EMBO ubiquitin conference in Cavtat.
We congratulate Dr Jason Collins from the National Institute of Dental and Craniofacial Research / NIH, Bethesda, USA with the First Poster Prize award at the EMBO ubiquitin conference in Cavtat.
Poster Prize awardees at the Biochemical Society conference in Edinburgh.
We congratulate the Poster Prize awardees at last week's Deubiquitylases and Ubl-proteases conference of the Biochemical Society in Edinburgh!
Launch of four new activity-based probes.
We have developed four new activity-based probes: HA-Ahx-Ahx-Ub-VAE (VAE= vinyl azido ester, human sequence, synthetic); UbiQ code: UbiQ-216 HA-Ahx-Ahx-Ub-VAA (VAA= vinyl azido amide, human sequence, synthetic); UbiQ code:
Moving our offices & laboratories.
We are happy and proud to announce that we have moved our office and labs to a brand new building at Science Park 301, just a five minutes walk from our old laboratories in the...
Launch of an activity-based probe designed to selectively target USP7.
We hereby announce the launch of an activity-based probe that is designed to selectively target USP7: K58K(biotin) cRh110-Cys-Ubv(USP7)-PA (UbiQ-314). UbiQ-314 is based on Ub with the following mutations: T7D, L8Y, I13R, E34L, Q40N, L69A, and L71A....
where to meet us
Lorne UBIQUITIN; the Australian Ubiquitin summit, 2025
November 20 - 23, 2025 Lorne, Australia Lorne UBIQUITIN; the Australia Ubiquitin summit, 2025 Contact: Farid El Oualid (CSO, attending the conference) and Alfred Nijkerk (CEO, sponsorship)
Innovation For Health 2025
April 3, 2025 Rotterdam, the Netherlands Innovation For Health 2025 Contact: Alfred Nijkerk (CEO)
GRK2243 Symposium Understanding Ubiquitylation: From Molecular Mechanisms to Disease, 2025
June 2 - 4, 2025 Würzburg, Germany GRK2243 Symposium Understanding Ubiquitylation: From Molecular Mechanisms to Disease, 2025 Contact: Farid El Oualid (CSO) and Alfred Nijkerk (CEO) (sponsorship)
International Plant Proteostasis Conference 2024
September 17 - 20, 2024 Vienna, Austria International Plant Proteostasis Conference 2024 Contact: Farid El Oualid (CSO) (sponsorship)
EMBO conference on Ubiquitin 2024
September 27 - October 1, 2024 Cavtat, Croatia Ubiquitin and ubiquitin-like proteins in health and disease. Contact: Alfred Nijkerk (CEO)
2nd Severo Ochoa Conference: Ligating the Ubiquitin Family; Physiology, Disease, and Future Directions June 2024
June 24 - 25, 2024 Bilbao, Spain 2nd Severo Ochoa Conference: Ligating the Ubiquitin Family; Physiology, Disease, and Future Directions June 2024 Contact: Farid El Oualid (CSO) (sponsorship)
Ubiquitin & Friends Symposium May 2024
May 2 - 3, 2024 Vienna, Austria Ubiquitin & Friends Symposium May 2024 Contact: Farid El Oualid (CSO) (sponsorship)
our publications
USP1/UAF1 targets polyubiquitinated PCNA with an exo-cleavage mechanism that can temporarily enrich for monoubiquitinated PCNA.
UbiQ is proud to have contributed to this paper in Nature Communications. Nat Commun 16, 6991 (2025). https://doi.org/10.1038/s41467-025-61768-0 USP1/UAF1 targets polyubiquitinated PCNA with an exo-cleavage mechanism that can temporarily enrich for monoubiquitinated PCNA. Niels Keijzer, Jan Sakoltchik, Kaustav...
Characterization of the Ubiquitin and ISG15 Deconjugase Activity of SARS-CoV-1 and SARS-CoV-2 Papain-Like Protease.
UbiQ is proud to have contributed a chapter to the Methods in Molecular Biology book series (MIMB,volume 2591), together with the Department of Biochemistry & Structural Biology, University of...
Catalytic and regulatory mechanisms of the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6.
UbiQ is proud to have been part of a major collaborative research project focused on studying the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6 and whose results have been reported recently in Nature Communications. Yuan et al. Crystal...
Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites.
21st Royal Society of Chemistry - Medicinal Chemistry Symposium, 13 - 15 September 2021, Cambridge UK. Poster title: A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis. Daniel Harris (1), Dr Mads Gabrielson (2), Dr...
Anti–COVID-19 Drug Design by targeting a molecular scissor of Ubiquitin and ISG15.
UbiQ is proud to have been part of a major collaboration reported recently by Rut et al. in Science Advances, describing the activity profiling and crystal structures of inhibitor bound SARS-CoV-2 PLpro: Activity profiling and crystal...
Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex.
Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites. Leishmaniasis is a neglected tropical disease caused by parasites...
Strategy for Development of Site-Specific Ubiquitin Antibodies.
As part of collaborative research between The Netherlands Cancer Institute, Leiden University Medical Centre, UbiQ and the University of Amsterdam, van Kruijsbergen et al. report in Frontiers in Chemistry detailed protocols for the development of...